Improved full-year guidance reflects continued momentum in Animal Health, vaccines and nutritional specialties
TEANECK, New Jersey | July 2026 – Phibro Animal Health Corporation has strengthened its financial outlook for fiscal year 2026 after delivering robust results through the first three quarters of the year. The global animal health company also reaffirmed its commitment to shareholders by declaring a quarterly cash dividend of US$0.12 per share, marking another quarter of consistent dividend payments.
The revised outlook reflects continued demand for the company’s animal health products, medicated feed additives, nutritional specialties and vaccines, reinforcing Phibro’s position as one of the leading global suppliers serving the livestock, poultry and aquaculture industries.
FY2026 Guidance Raised Following Strong Third Quarter
Following its third-quarter results, Phibro increased the lower end of several financial guidance ranges while maintaining confidence in sustained business momentum.
The company now expects for fiscal year ending June 30, 2026:
Financial Metric |
Updated FY2026 Guidance |
|---|---|
Net Sales |
US$1.46–1.50 billion |
Net Income |
US$92–100 million |
Diluted EPS |
US$2.25–2.44 |
Adjusted EBITDA |
US$247–255 million |
Adjusted Net Income |
US$122–127 million |
Adjusted Diluted EPS |
US$2.98–3.10 |
At the midpoint, management expects approximately:
-
14% year-over-year growth in revenue
-
Nearly 100% growth in net income
-
Around 37% growth in adjusted EBITDA
-
Approximately 45% growth in adjusted adjusted EPS
The guidance improvement follows stronger-than-expected operating performance and improved visibility into fourth-quarter trading.
Guidance Has Improved Throughout FY2026
One notable feature of Phibro’s fiscal 2026 performance has been the steady improvement in management’s outlook.
Reporting Period |
Revenue Guidance |
Initial FY2026 Guidance (August 2025) |
US$1.43–1.48 billion |
After Q2 Results |
US$1.45–1.50 billion |
After Q3 Results |
US$1.46–1.50 billion |
Rather than issuing a single upward revision, the company has progressively increased the lower end of its sales forecast as business performance strengthened through the year, signalling growing management confidence.
Strong Third Quarter Supports Higher Outlook
For the third quarter ended March 31, 2026, Phibro reported another solid set of financial results.
Metric |
Q3 FY2026 |
YoY Growth |
Net Sales |
US$383.5 million |
+10% |
Net Income |
US$24.0 million |
+15% |
Diluted EPS |
US$0.59 |
+16% |
Adjusted EBITDA |
US$60.8 million |
+11% |
Adjusted Net Income |
US$31.2 million |
+19% |
Adjusted EPS |
US$0.76 |
+19% |
Growth was primarily driven by the Animal Health business, where sales increased 13%, supported by strong demand for medicated feed additives, nutritional specialty products and vaccines.
Momentum Built Across the First Three Quarters
The third-quarter performance follows an exceptionally strong second quarter.
Q2 FY2026 Highlights
-
Revenue: US$373.9 million (+21%)
-
Net income: US$27.5 million
-
Adjusted EBITDA: US$68.1 million (+41%)
-
Adjusted EPS: US$0.87 (+58%)
Combined with continued first-quarter execution, these results demonstrate consistent operational momentum throughout fiscal 2026, giving management confidence to raise expectations for the full year.
Comparison With FY2025
Phibro enters the final quarter of fiscal 2026 after a record fiscal 2025, which itself delivered impressive growth.
FY2025 Results
Metric |
FY2025 |
Net Sales |
US$1.296 billion |
Net Income |
US$48.3 million |
Adjusted EBITDA |
US$183.7 million |
Adjusted EPS |
US$2.09 |
Compared with these results, the midpoint of FY2026 guidance implies:
-
Revenue approaching US$1.48 billion
-
Nearly US$96 million in net income
-
Around US$251 million adjusted EBITDA
-
Approximately US$3.04 adjusted EPS
If achieved, fiscal 2026 would represent another record year for the company across several key financial metrics.
Animal Health Remains the Primary Growth Driver
The company’s Animal Health segment continues to be the largest contributor to growth.
Demand remains healthy across:
-
Livestock nutritional specialty products
-
Medicated feed additives
-
Poultry health products
-
Vaccines
-
Companion animal products
-
Global distribution markets
Management also highlighted continued international demand and expansion of its sustainability-focused product portfolio as additional growth drivers.
Balance Sheet and Liquidity Strengthened
Beyond operating performance, Phibro has also improved its financial flexibility.
Key balance sheet highlights include:
-
US$77.5 million in cash and short-term investments
-
Gross leverage ratio of 3.1x
-
Revolving credit facility expanded by US$125 million, increasing total available commitments to US$435 million
